Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a Healthcare company (Biotechnology) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
Arcutis Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $27.15, Arcutis Biotherapeutics, Inc. trades at 116.7x trailing earnings, 6.7x sales and 14.6x book value, with an EV/EBITDA of 78.4. Over the last twelve months it generated about $509M of revenue and $29M of net income. It runs a gross margin of 91.2%, an operating margin of 6.9% and a net margin of 5.9%. It shows return on equity of 14.2%, return on invested capital of 9.5% and a free cash flow yield of 1.7%. On the balance sheet: a debt-to-equity ratio of 0.47 and a current ratio of 2.92. Over the past 52 weeks the share price ranged from $19.30 to $34.80, with a beta of 1.63.
Arcutis Biotherapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.